Peak HumanDatabase
    All Interventions

    Dulaglutide

    Pharmaceuticals
    GLP-1 Receptor Agonists

    Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist with proven cardiovascular benefits and a user-friendly auto-injector. It offers moderate efficacy with strong adherence due to its simple delivery system.

    Evidence Summary

    8
    / 10Score
    Strong
    Good Clinical Evidence

    REWIND trial (n=9,901) showed 12% reduction in MACE with notable inclusion of primary prevention patients (31% without established CVD). Moderate weight loss compared to semaglutide/tirzepatide.

    Evidence Scale

    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    AnecdotalStrong RCT

    Mechanism of Action

    GLP-1 receptor agonist fused to a modified IgG4 Fc fragment, extending half-life to ~5 days. Enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and promotes satiety through central nervous system GLP-1 receptor activation.

    Who Is This For?

    Type 2 diabetes with cardiovascular risk. Patients prioritizing device simplicity. Primary cardiovascular prevention in diabetic patients.

    Protocol & Dosing

    Dose

    Start 0.75mg weekly for 4 weeks, then increase to 1.5mg weekly. Maximum dose: 4.5mg weekly.

    Frequency

    Weekly injection

    Duration

    Ongoing / Long-term

    Protocol Summary

    Weekly subcutaneous injection via pre-filled auto-injector. REWIND trial uniquely included primary CV prevention population. Moderate efficacy but highest ease-of-use rating.

    Interactions & Precautions

    Contraindications

    • Medullary thyroid carcinoma history
    • MEN2
    • Severe GI disease
    • Pancreatitis history

    Potential Risks

    • •Thyroid tumor risk
    • •Pancreatitis
    • •Gallbladder events

    Potential Side Effects

    Nausea
    Diarrhea
    Abdominal pain
    Decreased appetite
    Fatigue

    Practitioner Notes

    Clinical annotations from Dr. Goel

    Good option for patients who value simple injection technique. Less weight loss than semaglutide — manage expectations. Consider for primary CV prevention based on REWIND data. Upgrading to semaglutide common if greater weight loss desired.
    SG

    Dr. Sanjeev Goel

    Chief Medical Officer, Peak Human

    Cost & Access

    Cost Range

    $$$

    Accessibility

    Prescription Required

    Availability varies by location

    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation
    See your Peak Human Score How it works